Compare CAL & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAL | VNDA |
|---|---|---|
| Founded | 1878 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.1M | 361.4M |
| IPO Year | 1994 | 2005 |
| Metric | CAL | VNDA |
|---|---|---|
| Price | $12.77 | $5.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $15.00 | $14.90 |
| AVG Volume (30 Days) | 543.6K | ★ 626.6K |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | $85,513,000.00 | ★ $216,105,000.00 |
| Revenue This Year | $5.19 | $21.35 |
| Revenue Next Year | $2.45 | $37.40 |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | 0.46 | ★ 8.72 |
| 52 Week Low | $8.80 | $4.27 |
| 52 Week High | $15.04 | $9.91 |
| Indicator | CAL | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 45.89 |
| Support Level | $11.61 | $4.94 |
| Resistance Level | $14.06 | $5.62 |
| Average True Range (ATR) | 0.69 | 0.17 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 44.36 | 27.14 |
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - Famous Footwear and Brand Portfolio. The Famous Footwear segment is comprised of its Famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. This segment is comprised of wholesale operations that designs, develops, sources, manufactures, markets and distributes branded, licensed and private-label footwear. Geographically, the company generates the majority of its revenue from Domestic operations.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.